PBAC's latest decision on Liposomal daunorubicin and cytarabine: Recommended with restriction (2024). Considered for Treatment of newly diagnosed therapy-related acute myeloid leukaemia (t-AML) or acute myeloid leukaemia with myelodysplasia-related changes (AML-MRC) in patients without prior chemotherapy induction and without FLT3-ITD/TKD mutations or favourable cytogenetic risk.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
1
first 2024
Submissions
1
2024 → 2024
Eligible population
Adults with newly diagnosed therapy-related acute myeloid leukaemia (t-AML) or acute myeloid leukaemia with myelodysplasia-related changes (AML-MRC), without prior chemotherapy induction, without FLT3-ITD/TKD mutations, without favourable cytogenetic risk, and with WHO performance status ≤2.
Therapy area
Haematology
Line of therapy
First-line
Evidence base
Other
Economic model
Not modelled
ICER note
Not modelled; this is an interim administrative listing on Section 100 HSD while system and IT issues for EFC listing are resolved. No economic evaluation conducted.